Immunotherapy Potential in Ovarian Cancer

28 Million Americans are currently fighting cancer. However, with ongoing cancer research and new combination treatments, patients have a better understanding of what to expect from various types of cancer. Immunotherapy has been slower to demonstrate progress in gynecologic cancers than in several other solid tumors, experts say. “We have not increased the number of…

Details

HPV Related Head and Neck Cancer Treatment Developments

HPV Related Head and Neck Cancer Treatment Developments

Head and neck cancer linked to HPV (human papilomavirus infection) is becoming increasingly common. A new form of treatment is in development, involving low-dose radiation. Check out a recent release covering this treatment, from Memorial Sloan Kettering Cancer Center, below. The number of head and neck cancers related to human papillomavirus (HPV) infection has surged…

Details

Gratitude Letter at Moffitt Cancer Center

Moffitt Cancer Center’s M2Gen Receives Investment from Hearst

Moffitt Cancer Center is a proud supporter and corporate partner of C3 For Change. The center’s health informatics subsidiary, M2Gen, recently received an equity investment by Hearst, a leader in healthcare technology. Check out a portion of the press release, below. NEW YORK and TAMPA, FLA. — Hearst, a market leader in healthcare technology, announced…

Details

September is Pediatric Cancer Awareness Month

September is Pediatric Cancer Awareness Month

The month of September is dedicated to raising awareness for Pediatric Cancer. Did you know that only 4% of funds raised for cancer research benefit pediatric cancer research? Most children and teens with cancer are treated at large pediatric cancer centers. Pediatric cancer treatment is usually offered to children from birth to age 18 or…

Details

Gratitude Letter at Moffitt Cancer Center

Moffitt Cancer Center Researchers Assist in New HPV Prevention Study

The human papillomavirus (HPV) is linked directly to one of the most deadly forms of cancer, cervical cancer. However, a new study published earlier this week in The Lancet reveals that researchers, including those from Moffitt Cancer Center, have found great success in HPV prevention through vaccination. TAMPA, Fla. – Cervical cancer is the second…

Details

Take a Loved One for Checkup Day

Take a Loved One for Checkup Day

Did you know that every third Tuesday of September is Take a Loved One for a Checkup Day? Created as a reminder to help friends and family visit with a health care professional, it’s definitely a date to mark on the calendar. Read more about the day, below. According to the US Department of Health…

Details

Age a Factor in SLNB Recommendations for Patients with Thin Melanomas

Age Factor in SLNB Recommendations for Patients with Thin Melanomas

According to the results of a study recently published in JAMA Dermatology, patient age may be a contributing factor in determining SLNB recommendations in cases of thin melanomas. “Patient age was shown to be an important discriminant of nodal positivity among patients with mitogenic tumors 0.50 to 0.75 mm and 0.76 to 1.0 mm and…

Details

Personalize Radiation Therapy: The Goal Of Moffitt Cancer Center & Cvergenx

Personalize Radiation Therapy: Moffitt Cancer Center & Cvergenx

Collaborating on a project called the Future of Radiation Therapy—aimed at revolutionizing radiation therapy, Moffitt Cancer Center and Cvergenx are providing a personalized radiation treatment plan based on the patients genetic framework! Read on, below, for more information!  Moffitt’s Radiation Oncology Department will utilize Cvergenx’s Genomic-Adjusted Radiation Dose (GARD) model. GARD is the first validated…

Details